A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.

Trial Profile

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs ARGX 111 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors argenx
  • Most Recent Events

    • 07 Jul 2017 Results published in an Argenx media release.
    • 07 Jul 2017 According to an Argenx media release, abstract covering the complete data set from this trial was presented at American Society of Clinical Oncology (ASCO) program at the 3rd Singapore Society of Oncology Annual Scientific Meeting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top